Passage Bio Inc (NASDAQ:PASG)’s traded shares stood at 0.36 million during the last session, with the company’s beta value hitting 1.45. At the close of trading, the stock’s price was $0.77, to imply an increase of 9.15% or $0.06 in intraday trading. The PASG share’s 52-week high remains $1.79, putting it -132.47% down since that peak but still an impressive 41.56% since price per share fell to its 52-week low of $0.45. The company has a valuation of $47.86M, with an average of 2.13 million shares in intraday trading volume over the past 10 days and average of 540.79K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Passage Bio Inc (PASG), translating to a mean rating of 1.00. Of 4 analyst(s) looking at the stock, 0 analyst(s) give PASG a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.24.
Passage Bio Inc (NASDAQ:PASG) trade information
After registering a 9.15% upside in the last session, Passage Bio Inc (PASG) has traded red over the past five days. The 5-day price performance for the stock is -31.42%, and 19.60% over 30 days. With these gigs, the year-to-date price performance is -23.27%. Short interest in Passage Bio Inc (NASDAQ:PASG) saw shorts transact 1.64 million shares and set a 6.61 days time to cover.
The extremes give us $6 and $6 for target low and target high price respectively. As such, PASG has been trading -679.22% off suggested target high and -679.22% from its likely low.
Passage Bio Inc (PASG) estimates and forecasts
Looking at statistics comparing Passage Bio Inc share performance against respective industry, we note that the company has outperformed competitors. Passage Bio Inc (PASG) shares are -34.60% down over the last 6 months, with its year-to-date growth rate higher than industry average at 44.09% against 17.50%.
PASG Dividends
Passage Bio Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Passage Bio Inc (NASDAQ:PASG)’s Major holders
Passage Bio Inc insiders hold 0.49% of total outstanding shares, with institutional holders owning 59.68% of the shares at 59.98% float percentage. In total, 59.68% institutions holds shares in the company, led by ORBIMED ADVISORS LLC. As of 2024-06-30, the company held over 10.12 million shares (or 17.9847% of shares), all amounting to roughly $8.04 million.
The next major institution holding the largest number of shares is VESTAL POINT CAPITAL, LP with 6.05 million shares, or about 10.7504% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $4.81 million.
